February 2021

India

India Pharma Export Industry’s current revenue is around USD 20 Billion with 8% growth rate and Contract Manufacturing business is also growing steadily in this segment.

The contract manufacturing business is taking strategic role in new drug discovery and development and offering solutions like:

• Identifying/Developing materials for R&D purposes in small quantities;
• Optimise process & scaling quantities for clinical studies; and
• Commercial scale production to fulfil commercial needs of the market

SCIN Life Science Team is also focusing on this pathway – developing contract manufacturing business in India for Japanese Innovator pharma companies.

We have successfully established contract manufacturing project wherein Japanese Innovator Pharma Company shared their technical process and Indian supplier developed and optimised the process from gms (grams) scale to MT (Metric Ton) scale commercially. Based on this strong technical capability, the supplier’s core technical team was invited to Innovator Pharma Company’s Japan plant wherein they exhibited their critical production process and later this critical step process was also transferred to India.

Our Indian supplier invested/installed similar equipment and exhibited the batch process successfully in commercial scale and currently manufacturing more than 5 MT of this product.

In 2019, Japanese Innovator Pharma Company obtained the New Drug Approval – Diabetic Neuropathic Pain application and has been successfully selling their final product in Japan. This project has been major trendsetter for our Life Science Department and we now are focusing to diversify our business in this area to increase the earning power of SCIN.